QTRX - Quanterix Corp
IEX Last Trade
11.12
-0.080 -0.719%
Share volume: 5,569
Last Updated: Thu 26 Dec 2024 08:30:07 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$11.20
-0.08
-0.71%
Fundamental analysis
8%
Profitability
0%
Dept financing
5%
Liquidity
75%
Performance
0%
Performance
5 Days
-1.22%
1 Month
-12.77%
3 Months
-18.95%
6 Months
-14.19%
1 Year
-62.70%
2 Year
-18.45%
Key data
Stock price
$11.12
DAY RANGE
$10.42 - $11.21
52 WEEK RANGE
$10.50 - $29.70
52 WEEK CHANGE
-$63.29
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Masoud Toloue
Region: US
Website: quanterix.com
Employees: 460
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: quanterix.com
Employees: 460
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Quanterix Corporation engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; SR-X and SP-X instruments. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation.
Recent news